Home
Learn More
Features & Pricing
Success Stories
Contact Us
Search Archives
PRWeb Direct
Submit Release
July 24, 2008
 
Industry Categories  
News by Country  
News by MSA  
Todays News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Web site.
 
All Press Releases for May 13, 2004 Subscribe to this News Feed      
 

Rapid Progression in Ion Channel Drug Discovery are Expected

BioSeeker Group has studied new progress in ion channel drug discovery. Several factors point towards a fast development in this field. Increased knowledge of novel targets in combination with a strong progress in drug discovery technologies has strongly contributed to this fast development. Resulting in a variety of commercial opportunities.

(PRWEB) May 13, 2004 -- Ion channels play a significant role in a great number of cell types and occur as large families of related genes with cell-specific expression patterns. Considering the access to the human genome, progress in transcription profiling revealing the tissue specific distributions of ion channels, they will play a much more important role as therapeutic drug targets in the future. Dysfunction of ion channels is related with many common diseases, such as cardiac arrhythmias, diabetes, hypertension, angina pectoris and epilepsy.
One of the main obstacles for the drug discovery companies has been to screen for compounds interacting with ion channels in an efficient way. Moreover, the last two years have resulted in important developments of the current screening techniques, and as a result it is possible that we will witness a breakthrough for the ion channel drug discovery companies in the next century.

BioSeeker Group has analyzed the technical development of ion channel drug screening techniques such as ion- flux-, patch-clamping, patch-on-a-chip and high-throughput assays. Moreover, an in-depth review of the current targets and drugs in ion channel R&D in both pre-clinical and clinical developmental stage has been analyzed.

Read more www.BioSeeker.com

OPTIONS
Printer Friendly Version
Email this story to a colleague
CONTACT INFORMATION
Anders LanzÉn
BIOSEEKER Group
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your login.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these releases. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright